Emerging Role of Phosphodiesterase 2A in Hypertension

Roland Seifert

Phosphodiesterases cleave and, thereby, inactivate the second messengers adenosine cAMP and cGMP. Phosphodiesterases are classified according to their preference for cAMP or cGMP. Phosphodiesterase 2 belongs to a class of phosphodiesterases that hydrolyze cAMP and cGMP with similar kinetics. Several recent studies point to a hitherto underappreciated pathophysiological and therapeutic relevance of phosphodiesterase 2 in cardiovascular diseases. Specifically, phosphodiesterase 2 upregulation in heart failure desensitizes the heart toward stimulation via $\beta_1$-adrenergic receptors. In engineered connective tissue, phosphodiesterase 2 enhances the conversion of fibroblasts to myofibroblasts, talk between cAMP and cGMP signaling. But in the study of Li et al, there is no evidence for a cross-regulatory role of phosphodiesterase 2A between cAMP and cGMP. In agreement with the data on rat sympathetic neurons studied by Li et al, in the failing rat heart, phosphodiesterase 2 is the major enzyme responsible for regulation of BNP-induced cGMP increase. An explanation for this high degree of specificity could be that all components of the BNP-particulate guanylyl cyclase A-PKG-phosphodiesterase 2 signaling pathway are localized in a defined cGMP-specific signalosome in sympathetic neurons and the failing ventricle, excluding cross talk with cAMP.

Second, in sympathetic neurons from spontaneously hypertensive rats, the expression of phosphodiesterase 2A is increased by $\approx 60\%$. Overexpression of phosphodiesterase 2A in sympathetic neurons, mimicked by adrenoviral infection, abrogates the inhibitory effects of BNP on calcium influx and norepinephrine release, and inhibition of this enhanced phosphodiesterase 2A activity with a selective phosphodiesterase 2 inhibitor restores the inhibitory effects of BNP on calcium influx and norepinephrine release. Thus, Li et al have identified a new molecular mechanism, namely enhanced phosphodiesterase 2A expression, by which beneficial cardiovascular effects of BNP are annihilated.

The study of Li et al has important implications for future research and therapeutic strategies. The genetic mechanisms underlying the upregulation of phosphodiesterase 2A in sympathetic neurons of spontaneously hypertensive rat are as yet unknown. It will be important to examine the question whether also other phosphodiesterases are dysregulated and which specific mechanisms are involved. Of course, it will be necessary to explore whether phosphodiesterase 2A expression is also altered in specific forms of human systemic hypertension. It should be kept in mind that phosphodiesterase 2 is not a single enzyme, but a family of 3 splice variants that may have slightly different functions. Moreover, in the study of Li et al on sympathetic neurons, phosphodiesterase 2A exhibited the properties of a cGMP-specific phosphodiesterase (Figure), but in other systems phosphodiesterase 2 regulates both cAMP and cGMP. This may reflect differential compartmentalization of proteins involved in cAMP and cGMP signaling.

About therapeutic interventions, 1 evident strategy based on the results of Li et al is to enhance the clinical effects of BNP derivatives such as nesiritide with phosphodiesterase 2 inhibitors. On the basis of different mechanisms of action, we may expect synergistic beneficial cardiovascular effects. A dual therapy with a particulate guanylyl cyclase A agonist and a phosphodiesterase 2 inhibitor entails, of course, the risk of increased side effects, specifically in cells that express both particulate guanylyl cyclase A and phosphodiesterase 2A. But it is certainly worthwhile to pursue this avenue of drug research.

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Institute of Pharmacology, Hannover Medical School, Hannover, Germany.

Correspondence to Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Straße 1, D-30625 Hannover, Germany. E-mail seifert.roland@mh-hannover.de


Hypertension is available at http://hyper.ahajournals.org DOI: 10.1161/HYPERTENSIONAHA.115.05170
Role of phosphodiesterase 2 (PDE2) in the modulation of sympathetic neuron function by brain-derived natriuretic peptide (BNP). Depolarization of sympathetic nerve terminals leads to activation of voltage-dependent calcium channels (VOCC). The calcium influx results in the release of norepinephrine (NE), which via β-adrenergic receptors increases heart rate and, via α1-adrenergic receptors, increases vascular resistance. As a result, blood pressure increases. This pathway is functionally antagonized by BNP, which activates the particulate guanylyl cyclase A (pGC-A). pGC-A catalyzes the cyclization of GTP to the second messenger guanosine cGMP, which in turn activates protein kinase G (PKG, also referred to as cGMP-dependent protein kinase). As a result, calcium influx, NE release, and heart rate are decreased. cGMP is inactivated by PDE2. Overexpression of PDE2 in spontaneously hypertensive rats (SHR) or adrenoviral overexpression of PDE2 in sympathetic neurons abrogates the inhibitory effects of BNP on calcium influx and norepinephrine release. In contrast, the selective PDE2 inhibitor BAY 60-7550 restores the inhibitory actions of BNP. As a control, the selective PDE3 inhibitor milrinone is ineffective. BAY 60-7550 indicates a prototypical selective PDE2 inhibitor; isatin, a compound with pleiotropic pharmacological effects including blockade of pGC-A activation by BNP; milrinone, a prototypical selective PDE3 inhibitor; and Rp-8-Br-PET-cGMP, a selective and membrane-permeable inhibitor of PKG.

A recent study provided proof-of-concept that phosphodiesterase 2 inhibition exerts beneficial effects in several preclinical models of pulmonary hypertension.9 As a next step, similar studies should be conducted with respect to systemic arterial hypertension. Several potent and selective phosphodiesterase 2 inhibitors have been developed based on the crystal structure of phosphodiesterase 2A and systematic structure–activity relationship studies of compound series.9,10 Currently, the focus of clinical phosphodiesterase 2 inhibitor research is on the treatment of neuropsychiatric diseases associated with cognitive impairment, such as Alzheimer disease, schizophrenia, and depression. Given the high prevalence of Alzheimer disease, depression, and hypertension, phosphodiesterase 2A inhibitors may perhaps become the first class of drugs to simultaneously treat both cardiovascular and neuropsychiatric diseases. Phosphodiesterase 2 inhibitors that do not penetrate the blood–brain barrier are available, as well.5,10 In view of the fact that phosphodiesterase 2A hydrolyzes both cAMP and cGMP and is stimulated by cGMP1, it may be important to target just specific cell types to minimize side effects.

In conclusion, the present study of Li et al.5 together with other reports, most notably the study by Bubb et al.10 on pulmonary hypertension, have placed the concept of phosphodiesterase 2 inhibition in a prominent position for future pathophysiologial and pharmacological research. The study of Li et al.10 is an excellent example how substantial progress can be obtained through wise application of pharmacological and molecular biology methods in appropriate (patho)physiological models.

Acknowledgments

I thank Annette Stanke for preparation of the Figure and critical reading of the article.

Disclosures

None.

References

Emerging Role of Phosphodiesterase 2A in Hypertension
Roland Seifert

Hypertension. 2015;66:13-14; originally published online April 27, 2015;
doi: 10.1161/HYPERTENSIONAHA.115.05170

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/66/1/13

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/